| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Common Stock | Sale | $842,213 | -2,009 | -6.6% | $419.22 | 28,291 | 12 Feb 2024 | Direct | F1, F2, F3 |
| transaction | VRTX | Common Stock | Sale | $271,992 | -647 | -2.3% | $420.39 | 27,644 | 12 Feb 2024 | Direct | F1, F2, F4 |
| transaction | VRTX | Common Stock | Sale | $308,899 | -737 | -2.7% | $419.13 | 26,907 | 13 Feb 2024 | Direct | F1, F2, F5 |
| holding | VRTX | Common Stock | 440 | 12 Feb 2024 | 401(k) |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023. |
| F2 | Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| F3 | Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71). |
| F4 | Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94). |
| F5 | Open market sales reported on this line occurred at a weighted average price of $419.13 (range $419.00 to $419.37). |